Public Health

Health Products Regulatory Authority (HPRA) safety notices

Click here for details.

Picato (ingenol mebutate)

Suspension of the marketing authorisation due to risk of skin malignancy » read more

WHO IHR emergency committee decision on novel coronavirus outbreak in China

Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus 2019 (n-CoV) on 23 January 2020 » read more

WHO Euro-Update on Novel Corona virus (2019-nCoV) in Wuhan China - Guidance and update

Following the news of an outbreak of a novel corona virus (2019-nCoV) in Wuhan, China, the WHO Regional Office would like to share with you some updated sources of information. There has been significant interest in ensuring European Region Member States are prepared should the Region be affected. » read more

Updated ECDC Rapid Risk Assessment: Cluster of pneumonia cases caused by a novel coronavirus, Wuhan, China, 2020

Since 31 December 2019 and as of 17 January 2020, 205 laboratory confirmed cases of novel coronavirus 2019-nCoV infection, including three deaths (case fatality ratio: 1.5%), have been reported in Wuhan City, China. In addition, three cases of 2019-nCoV have been reported in Beijing (2) and Guangdong (1) in China, all with a travel history to Wuhan. A further four imported cases ex-Wuhan have been reported in Thailand (2), Japan (1) and South Korea (1). » read more

EMA suspends Picato as a precaution while review of skin cancer risk continues

In September 2019, at the request of the European Commission, the European Medicines Agency's safety committee (the Pharmacovigilance Risk Assessment Committee - PRAC) commenced a review of data on skin cancer in patients using Picato (ingenol mebutate), a gel indicated for the treatment of cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. The product information includes a warning in relation to keratoacanthoma and was updated to also include basal cell ca » read more

Influenza season 2019-2020 early situation assessment from ECDC and WHO Euro

Please find a link to the ECDC/WHO early situation assessment for the 2019/2020 influenza season which was released today Wednesday December 18. » read more

Antiviral notice to Health Care Professionals - Influenza

The most recent influenza surveillance data indicate that influenza-like illness (ILI) has increased in the community in the past week. The influenza-like illness (ILI) rate during week 49 (week ending December 8th 2019) was 37.5 per 100,000 population which is now above the Irish baseline ILI threshold of 18.1 per 100,000 for the first time this season. » read more

Recommendations to avoid potentially fatal dosing errors when using methotrexate for inflammatory diseases

Pfizer Direct Healthcare Professional Communication » read more

Pregabalin and Gabapentin Medicinal Products designated interchangeable

In line with its remit under the Health (Pricing and Supply of Medical Goods) Act 2013, the Health Products Regulatory Authority (HPRA) will include pregabalin and gabapentin-containing medicinal products on the List of Interchangeable Medicines. » read more

European Medicines Agency review of Xeljanz (Article 20 Referral)

The European Medicines Agency's safety committee (PRAC) has concluded a review of Xeljanz (tofacitinib) and recommended updates to product information and new risk minimisation measures. » read more

Email:, Tel: 01 6763705, Fax: 01 6765850
Learn More To give you the best possible experience, our sites use cookies. Continuing with cookies enabled means you're OK with this. Click Learn More for more information about our cookies, and how to disable them. ×